Although these oncogenic mutations commonly occur in benign melanocytic precursor lesions (naevi), accumulation of oncogenic mutations or loss of tumor-suppressor genes, such as CDKN2A, PTEN, or TP53, drives progression to melanoma. This evidence concerns the gene TP53 and melanoma.